Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects

Pharmacogenomics Journal

Volumn 13, Issue 1, 2013, Pages 1-11

  Sim, S C ^a   Kacevska, M ^a   Ingelman Sundberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

cardiovascular; conjugation; cytochrome P450; exogenous; hepatic; toxicity

Indexed keywords

ACENOCOUMAROL; ANTIDEPRESSANT AGENT; ARYLDIALKYLPHOSPHATASE 1; AZATHIOPRINE; BILIRUBIN; CLOPIDOGREL; CODEINE; CYCLOSPORIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; EFAVIRENZ; ESCITALOPRAM; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MERCAPTOPURINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHASE I DRUG METABOLIZING ENZYME; PHASE II DRUG METABOLIZING ENZYME; PRASUGREL; TACROLIMUS; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN FUNCTION; BREAST CANCER; BREATHING DISORDER; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; COFFEE; COLORECTAL CANCER; CONFUSION; CROHN DISEASE; CYP1A1 GENE; CYP1A2 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A5 GENE; DEPRESSION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LEUKEMIA; LUNG CANCER; META ANALYSIS (TOPIC); NEUROTOXICITY; NONHUMAN; PAIN; PHARMACOGENOMICS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; SMOKING; SOMNOLENCE; SUICIDAL BEHAVIOR; TPMT GENE; TREATMENT OUTCOME; UGT1A1 GENE;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 84872899545     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.45     Document Type: Review

References (120)

1. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 2011; 32: 72-81.
2. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet 2011; 20: 528-540.
3. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008; 28: 992-998.
4. Sadee W, Wang D, Papp AC, Pinsonneault JK, Smith RM, Moyer RA et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther 2011; 89: 355-365.
5. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422.
6. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8: 129-135.
7. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
8. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319: 1322-1326.
9. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M et al. Aberrant splicing caused by single nucleotide polymorphism c.516G4T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325: 284-292.
10. Ehmer U, Kalthoff S, Fakundiny B, Pabst B, Freiberg N, Naumann R et al. Gilbert syndrome redefined: a complex genetic haplotype influences the regulation of glucuronidation. Hepatology 2012; 55: 1912-1921.
11. Aiello M, Vella N, Cannavo C, Scalisi A, Spandidos DA, Toffoli G et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Mol Med Report 2011; 4: 203-208.
12. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
13. Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C4A polymorphism. Eur J Clin Pharmacol 2010; 66: 697-703.
14. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002; 54: 540-543.
15. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11: 274-286.
16. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN et al. Genomewide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 2011; 7: e1002033.
17. Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KK et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet 2011; 20: 2071-2077.
18. Amin N, Byrne E, Johnson J, Chenevix-Trench G, Walter S, Nolte IM et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. Mol Psychiatry 2012; 17: 1031-1041.
19. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41: 666-676.
20. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478: 103-109.
21. Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, Papparella I et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 2009; 27: 1594-1601.
22. Guessous I, Dobrinas M, Kutalik Z, Pruijm M, Ehret G, Maillard M et al. Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. Hum Mol Genet 2012; 21: 3283-3292.
23. Gold AB, Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet advance online publication
24. January 2012 (e-pub ahead of print).
25. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42: 448-453.
26. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010; 42: 441-447.
27. Siedlinski M, Cho MH, Bakke P, Gulsvik A, Lomas DA, Anderson W et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 2011; 66: 894-902.
28. Tang DW, Hello B, Mroziewicz M, Fellows LK, Tyndale RF, Dagher A. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage 2012; 60: 2136-2143.
29. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011; 103: 1342-1346.
30. Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM et al. Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PloS One 2009; 4: e5652.
31. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25: 2451-2458.
32. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 890-894.
33. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
34. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
35. Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N et al. Genomewide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010; 19: 4735-4744.
36. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009; 18: 3758-3768.
37. Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-2812.
38. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW et al. Randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing: Couma-Gen-II. Circulation 2012; 125: 1997-2005.
39. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatinmediated cholesterol reduction in The Rotterdam Study. Pharmacogenet Genomics 2011; 21: 861-866.
40. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574-1583.
41. Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12: 1383-1396.
42. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C4T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics 2012; 22: 373-380.
43. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
44. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama 2009; 302: 849-857.
45. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. Jama 2011; 306: 2704-2714.
46. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012; 10: 199-206.
47. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588.
48. Liu YP, Hao PP, Zhang MX, Zhang C, Gao F, Zhang Y et al. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb Res 2011; 128: 593-594.
49. Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomas M et al. Meta-analyses of the association between cytochrome CYP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98: 100-108.
50. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K et al. Reducedfunction CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Jama 2010; 304: 1821-1830.
51. Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep 2011; 38: 1697-1702.
52. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-143.
53. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011; 11: 199-206.
54. Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22: 169-175.
55. Mega JL, Topol EJ, Sabatine MS. CYP2C19 genotype and cardiovascular events. Jama 2012; 307: 1482-1483author reply 1484-1485.
56. Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012; 91: 774-776.
57. Ten Berg JM, Deneer VH. Antiplatelet therapy: does CYP2C19 genotype affect clinical outcome? Nat Rev Cardiol 2012; 9: 192-194.
58. Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011; 97: 1239-1244.
59. Mega JL, Hochholzer W, Frelinger 3rd AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. Jama 2011; 306: 2221-2228.
60. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M et al. Point-ofcare genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379: 1705-1711.
61. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
62. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32: 1605-1613.
63. Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C et al. Paraoxonase-Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; 4: 429-436.
64. Irvin Jr. WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC et al. Genotypeguided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011; 29: 3232-3239.
65. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet 2012; 27: 122-131.
66. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718-725.
67. Cronin-Fenton DP, Lash TL. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev 2011; 4: 363-377.
68. Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 2010; 122: 609-617.
69. Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010; 16: 4468-4477.
70. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011; 125: 279-287.
71. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Jama 2009; 302: 1429-1436.
72. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 2012; 104: 441-451.
73. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-460.
74. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010; 12: R64.
75. Goldberg P. Experts claim errors in Breast Cancer Study, demand retraction of practice-changing paper. Cancer Letter 2012; 38: 1-7.
76. Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, Kubo M et al. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet 2012; 21: 1665-1672.
77. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193.
78. Moyer AM, Suman VJ, Weinshilboum RM, Avula R, Black JL, Safgren SL et al. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics 2011; 12: 1535-1543.
79. van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME et al. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics 2011; 12: 1137-1146.
80. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010; 85: 190-200.
81. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-2199.
82. Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25: 1271-1280.
83. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 2011; 66: 2092-2098.
84. Powers V, Ward J, Gompels M. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. HIV Med 2009; 10: 520-523.
85. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202: 717-722.
86. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
87. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18: 2391-2400.
88. Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit 2010; 32: 708-714.
89. Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 2011; 21: 713-720.
90. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004; 75: 386-393.
91. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803-807.
92. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010; 71: 1482-1487.
93. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010; 11: 537-546.
94. Penas-Lledo EM, Trejo HD, Dorado P, Ortega A, Jung H, Alonso E et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry advance online publication, 26 January 2012 (e-pub ahead of print).
95. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PloS One 2008; 3: e1872.
96. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30: 474-482.
97. Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009; 24: 250-256.
98. Penas-Lledo EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-Garcia E, Llerena A. CYP2D6 and the severity of suicide attempts. Pharmacogenomics 2012; 13: 179-184.
99. Penas-Lledo EM, Dorado P, Aguera Z, Gratacos M, Estivill X, Fernandez-Aranda F et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 2011; 16: 691-692.
100. Stingl JC, Viviani R. CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther 2011; 89: 352-353.
101. Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 2010; 88: 354-359.
102. Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 2012; 26: 398-407.
103. Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 2008; 64: 1181-1188.
104. Sim SC, Nordin L, Andersson TM, Virding S, Olsson M, Pedersen NL et al. Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1160-1166.
105. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011; 21: 1-9.
106. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91: 321-326.
107. Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer ML et al. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 2012; 91: 692-699.
108. Dorado P, Penas-Lledo EM, Llerena A. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 2007; 8: 1597-1608.
109. Kirchheiner J, Seeringer A, Godoy AL, Ohmle B, Maier C, Beschoner P et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 2011; 16: 237 333-241.
110. Stingl JC, Esslinger C, Tost H, Bilek E, Kirsch P, Ohmle B et al. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage 2012; 59: 2818-2823.
111. Joffe H, Deckersbach T, Lin NU, Makris N, Skaar TC, Rauch SL et al. Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET Study. J Clin Endocrinol Metab 2012; 97: 3207-3215.
112. Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009; 5: 607-620.
113. Estany-Gestal A, Salgado-Barreira A, Sanchez-Diz P, Figueiras A. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review. Pharmacogenet Genomics 2011; 21: 357-364.
114. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 2010; 16: 3832-3842.
115. Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol 2010; 24: 555-571.
116. Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 2009; 18: 2711-2718.
117. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009; 18: 2700-2710.
118. Chen G, Ramos E, Adeyemo A, Shriner D, Zhou J, Doumatey AP et al. UGT1A1 is a major locus influencing bilirubin levels in African Americans. Eur J Hum Genet 2012; 20: 463-468.
119. Fujiwara R, Nguyen N, Chen S, Tukey RH. Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus. Proc Nat Acad Sci Usa 2010; 107: 5024-5029.
120. Booth RA, Ansari MT, Loit E, Tricco AC, Weeks L, Doucette S et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011; 154: 814-823W-295-818.